|
See related Cancidas infusion information |
|
|
|
Manufacturer |
MSD |
|
Distributor |
Zuellig |
|
Contents |
Caspofungin acetate |
|
Indications |
Empirical therapy for presumed fungal infections in febrile, neutropenic patients. Treatment of invasive candidiasis in neutropenic & non-neutropenic patients; esophageal & oropharyngeal candidiasis; invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
Click to view Cancidas detailed prescribing infomation |
|
Dosage |
Adult ≥18 yr Empirical therapy/Invasive aspergillosis & candidiasis Single 70 mg loading dose on day 1, followed by 50 mg daily thereafter. Esophageal & oropharyngeal candidiasis 50 mg daily. Childn 3 mth-17 yr Single 70 mg/m2 loading dose on day 1, followed by 50 mg/m2 daily thereafter. Administer by slow IV infusion over approx 1 hr.
Click to view Cancidas detailed prescribing infomation |
|
Overdosage |
View Cancidas overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Hypersensitivity.
Click to view Cancidas detailed prescribing infomation |
|
Special Precautions |
Pregnancy & lactation. Can be used w/ cyclosporin when the potential benefit outweighs the potential risk.
Click to view Cancidas detailed prescribing infomation |
|
Adverse Drug Reactions |
Anaphylaxis, fever, headache, abdominal pain, pain, chills, nausea, diarrhea, vomiting, elevated liver enzyme levels, increased serum creatinine, anemia, tachycardia, catheter-site pain, phlebitis/thrombophlebitis, infused-vein complication, flushing, hypotension, dyspnea, rash, pruritus, sweating, facial swelling, sensation of warmth, bronchospasm.
View ADR Monitoring Form |
|
Side Effects |
View Cancidas side effects |
|
Drug Interactions |
Cyclosporine, tacrolimus, efavirenz, nevirapine, phenytoin, dexamethasone, carbamazepine, rifampin.
View more drug interactions with Cancidas |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Cancidas storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Cancidas description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Cancidas mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
